Inari Medical and Aidoc Form Partnership to Integrate AI Technology in Detection and Treatment of PE

April 14, 2021—Inari Medical, Inc., a developer of treatments for venous disease, announced a new global partnership with Aidoc, a provider of enterprise artificial intelligence (AI) solutions. The partnership seeks to accelerate the adoption and clinical impact of AI to advance timely detection and treatment of pulmonary embolism (PE).

Inari’s devices that address venous thromboembolism are the FlowTriever system, which is 510(k)-cleared by the FDA and CE Mark–approved for the treatment of PE and clot-in-transit in the right atrium, and the ClotTriever system, which is 510(k)-cleared by the FDA and CE Mark–approved for the treatment of deep vein thrombosis.

Elad Walach, Cofounder and Chief Executive Officer of Aidoc, stated, “We are the first company to offer an AI-based activation solution that facilitates rapid triage of patient scans with suspected positive findings for PE. Our Care Coordination suite includes Aidoc’s FDA-cleared solution for triage and notification of suspected PE together with Imbio’s FDA-cleared automated right ventricular–to–left ventricular analysis. The care team involved in the reading workflow can now harness our mobile app at their fingertips to synchronize on the patient treatment path, with access to real-time image, data, video, and chat features. We are extremely excited to be partnering with Inari and see the potential of this partnership to shift the standard of care in PE patient triage and treatment to advance a field that is ripe for innovation.”

Jonathan Paul, MD, who is Associate Professor of Medicine and Director of the PE program at the University of Chicago Medical Center in Chicago, Illinois, commented in the announcement, “The partnership between Inari and Aidoc is a natural fit. FlowTriever has become a frontline treatment option for intermediate and high-risk PE at our institution. We were proud to pilot and help refine the Aidoc PE suite and have integrated the commercial version of the software into our workflow. We have been pleased to see the impact Aidoc has had on quickly flagging studies with suspected PE findings and improving our patient outcomes.”